FDA allows temporary import of unapproved Chinese cancer drug to ease U.S. shortage

Photo caption: Worker labors on a production line at the factory of Qilu Pharmaceutical in Haikou, Hainan province of China, February 11, 2022. Photo credit: Su Bikun | VCG | Getty Images. Article by Spencer Kimball. CNBC – June 2, 2023.

Key Points:

• The U.S. Food and Drug Administration has given Qilu Pharmaceutical permission to ship cisplatin to the United States to ease a national cancer drug shortage.
• The drug maker’s cisplatin injections are manufactured and marketed in China. Cisplatin is widely used in chemotherapy to treat testicular, lung, bladder, cervical and ovarian cancers.
• The FDA earlier said it was considering allowing nonapproved drugs to be imported to alleviate the shortage. […]

Click here to view original web page at www.cnbc.com